Better Cancer Immunotherapy Drugs Through X-Ray Crystallography
May 30, 2017—(BRONX, NY)—Immunotherapy drugs to combat cancer have stimulated tremendous excitement among patients and physicians alike. They debuted in 2011, when the U.S. Food and Drug Administration approved ipilimumab (Yervoy) to treat metastatic melanoma, a usually fatal disease. Since then, other immunotherapies have reached the market, including pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq) and avelumab (Bavencio). (Source: Einstein News)
Source: Einstein News - May 30, 2017 Category: Universities & Medical Training Source Type: news
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Novel combinations of binimetinib, Opdivo® (nivolumab) and Yervoy® (ipilimumab) to be studied in colorectal cancer patients
BOULDER, Colo. and NEW YORK, May 30, 2017 -- (Healthcare Sales & Marketing Network) -- Array BioPharma (Nasdaq: ARRY) an... Biopharmaceuticals, Oncology Array BioPharma, Bristol-Myers Squibb, binimetinib, nivolumab, ipilimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 30, 2017 Category: Pharmaceuticals Source Type: news
Array BioPharma and Bristol-Myers Squibb announce strategic collaboration
Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's investigational MEK inhibitor, binimetinib in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors. (Source: World Pharma News)
Source: World Pharma News - May 30, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
Immunotherapies Show Promise in Small-Cell Lung Cancer
This video reviews immunotherapy trials in small-cell lung cancer, including studies on pembrolizumab, nivolumab monotherapy, and nivolumab in combination with ipilimumab. (Source: CancerNetwork)
Source: CancerNetwork - May 5, 2017 Category: Cancer & Oncology Authors: Gregory P. Kalemkerian, MD Tags: Videos Lung Cancer Source Type: news
Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo
NEW YORK (Reuters) - Bristol-Myers Squibb Co on Thursday reported higher-than-expected quarterly earnings, helped by increased sales of cancer drugs Opdivo and Yervoy and blood thinner Eliquis. (Source: Reuters: Health)
Source: Reuters: Health - April 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Bavarian Nordic commences Phase II combination trial for prostate cancer
Danish-based biotechnology firm Bavarian Nordic has commenced a Phase II clinical trial of Prostvac (rilimogene) in combination with Yervoy (ipilimumab) and / or Opdivo (nivolumab) to treat localised prostate cancer patients. (Source: Drug Development Technology)
Source: Drug Development Technology - April 19, 2017 Category: Pharmaceuticals Source Type: news
CheckMate 067 Shows OS Improved With Nivolumab/Ipilimumab in Melanoma
A nivolumab/ipilimumab combination significantly improved overall survival for advanced melanoma patients. (Source: CancerNetwork)
Source: CancerNetwork - April 10, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Conferences/AACR 2017 Melanoma News Source Type: news
First Phase 3 OS Results With Melanoma ImmunoTx Combo First Phase 3 OS Results With Melanoma ImmunoTx Combo
Nivolumab, alone or in combination with ipilimumab, was better than ipilimumab monotherapy in a phase 3 trial. But there ' s another pressing question with this first-of-its-kind clinical trial.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 7, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Yervoy (Ipilimumab Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 6, 2017 Category: Drugs & Pharmacology Source Type: news
Immunotherapy Combination Promising in Advanced Melanoma
The combination of an intratumoral injection of CVA21 and ipilimumab has demonstrated durable response with minimal toxicity in patients with advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news
For Bristol-Myers, A Victory And A Mystery
In a relief to investors, the combination of Opdivo and Yervoy extends survival in melanoma. More data being released this afternoon could yield answers to the question of why Opdivo did not show a benefit in previously untreated lung cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 3, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:BMY NYSE:MRK Source Type: news
The first overall survival data from the Phase 3 CheckMate -067 clinical trial
Bristol-Myers Squibb Company (NYSE:BMY) today announced the first overall survival (OS) data from the Phase 3 CheckMate -067 clinical trial. With a minimum follow-up of 28 months, the median OS had not yet been reached in either of the two Opdivo treatment groups and was 20 months for the Yervoy monotherapy group (95% CI: 17.1-24.6). Opdivo in combination with Yervoy and as a monotherapy reduced the risk of death 45% [hazard ratio (HR) 0.55; 95% CI: 0.42-0.72; P (Source: World Pharma News)
Source: World Pharma News - April 3, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
Questions Over Adjuvant Ipilimumab in Melanoma Questions Over Adjuvant Ipilimumab in Melanoma
An editorial raises questions on data for patient-reported outcomes for adjuvant ipilimumab, 10 mg/kg, in melanoma; toxicity also questioned.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 16, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
How this cancer immunotherapy pioneer is working to improve next-gen drugs
If anyone knows the knock on first-generation cancer immunotherapy drugs, it's Matthew Krummel. Now he's working with three big drug developers to improve next-generation cancer immunotherapies.
As a graduate student in the 1990s at the University of California, Berkeley, Krummel helped to discover the first "checkpoint inhibitor" — eventually developed by Bristol-Myers Squibb Co. as Yervoy — that helps the immune system identify otherwise cloaked cancer cells.
Checkpoint inhibitors, so-called… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 23, 2017 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
